Related Experiment Video
Updated: Sep 17, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187
Abstract:
Anthracyclines are amongst the most effective antitumor agents currently utilized. The major impediment to their use has been the development of cardiotoxicity with chronic administration. In an effort to overcome this limitation we have utilizated an approach to abrogate the cardiotoxicity with a drug, ICRF-187, which protects against the anthracycline cardiomyopathy in all animal species so far tested. This strategy assumes that separate mechanisms of cardiac toxicity and antitumor activity exist. We are currently testing this hypothesis in a randomized clinical trial of women with advanced breast cancer who are randomized to receive 5FU, doxorubicin, and cyclophosphamide (FAC) or FAC plus ICRF-187.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

